Overview

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

Status:
Completed

Trial end date:
2017-06-07

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to investigate the safety and tolerability of JNJ 54175446 in participants with Major Depressive Disorder (MDD).

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC